PHILADELPHIA, Nov. 02, 2026 (GLOBE NEWSWIRE) —
Aardvark Therapeutics, Inc. (NASDAQ: AARD):
Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ: AARD) shareholders who purchased shares on or shortly after the Company’s February 13, 2025, initial public offering (IPO) and have continued to hold their shares.
What is This Investigation About? The investigation follows the filing of a securities class action against Aardvark and certain of its officers and directors alleging violations of the federal securities laws in connection with statements concerning the safety and prospects of the Company’s lead drug candidate, ARD-101.
If you purchased Aardvark Therapeutics, Inc. (NASDAQ: AARD) shares on or shortly after the Company’s February 13, 2025 IPO, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever through a shareholder governance action. You are encouraged to visit https://grabarlaw.com/the-latest/aardvark-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085 to learn more.
What is Alleged? According to the recently filed securities complaint, Aardvark Therapeutics, Inc. (NASDAQ: AARD) IPO offering documents represented that ARD-101 had been “well-tolerated” in earlier clinical trials, had limited systemic absorption, and had demonstrated no serious adverse events. The complaint alleges that the offering documents were materially false or misleading because they failed to disclose that ARD-101 was less safe than investors had been led to believe and that its clinical, regulatory, and commercial prospects were therefore overstated.
The complaint further alleges that similar representations concerning ARD-101’s safety continued after the IPO. For example, Company representatives subsequently described ARD-101 as having a “very, very clean” safety profile and represented that its limited systemic exposure reduced the likelihood of side effects.
Then, on February 27, 2026, Aardvark announced that it was voluntarily pausing enrollment and dosing in the Phase 3 HERO trial after identifying reversible cardiac observations during safety monitoring in a healthy-volunteer study. Following the announcement, Aardvark’s stock price allegedly declined approximately 56%, closing at $5.47 per share on March 2, 2026.
Then, on May 14, 2026, Aardvark announced that the FDA had placed a full clinical hold on the investigational new drug application for ARD-101, including the Phase 3 HERO trial and its open-label extension. According to the complaint, Aardvark’s stock declined another 32.1% the following day, closing at $4.57 per share.
What Can You Do Now? If you purchased Aardvark shares at or shortly after the February 13, 2025 IPO, and continue to own those shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/aardvark-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085 to learn more. #AARD $AARD #Aardvark
Erasca, Inc. (NASDAQ: ERAS):
Grabar Law Office is investigating whether certain officers and directors of Erasca, Inc. (NASDAQ: ERAS) breached their fiduciary duties owed to the Company and its shareholders.
What is This Investigation About? The investigation concerns whether Erasca’s directors and senior executives maintained appropriate oversight, disclosure controls, compliance procedures, and risk-management systems relating to the Company’s public statements concerning ERAS-0015, a pan-RAS molecular glue candidate being developed for the treatment of RAS-mutant solid tumors.
If you are a current Erasca (NASDAQ: ERAS) shareholder who has held shares since prior to January 14, 2025, you seek corporate governance reforms, damages on behalf of the Company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/erasca-shareholder-investigation/, contact Joshua H. Grabar at jgrabar@grabarlaw.com, or call us at 267-507-6085.
What is Alleged? According to a recently filed federal securities class action Erasca, Inc. (NASDAQ: ERAS), through certain of its officers, made materially misleading statements and omissions concerning ERAS-0015. Among other things, the underlying class action complaint alleges that: Erasca publicly promoted ERAS-0015 as a potential “best-in-class” therapy and made repeated comparisons between ERAS-0015 and Revolution Medicines’ RMC-6236; the Company’s public disclosures allegedly relied upon improper comparisons to RMC-6236; Erasca allegedly faced intellectual property, patent, and trade-secret-related risks associated with those comparisons and related disclosures; investors allegedly were not adequately informed of those risks; and certain positive statements regarding ERAS-0015 allegedly lacked a reasonable basis when made.
On April 27, 2026, Erasca disclosed that it had received correspondence from counsel for Revolution Medicines alleging, among other things, patent infringement, trade-secret-related issues, and allegedly improper comparative statements concerning ERAS-0015 and RMC-6236. Later that same day, Erasca disclosed preliminary Phase 1 clinical data regarding ERAS-0015 and reported that one patient who received ERAS-0015 had died after experiencing pneumonitis that progressed following withdrawal of supportive care. The Company also disclosed that comparisons between ERAS-0015 and other product candidates were based on cross-study analyses rather than head-to-head clinical trials and that such comparisons were inherently limited. Following these disclosures, Erasca’s share price experienced a substantial decline.
What Can You Do Now? If you are a current Erasca, Inc. (NASDAQ: ERAS) shareholder and have held shares since prior to January 14, 2025, you can seek corporate governance reforms, damages on behalf of the Company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/erasca-shareholder-investigation/, contact Joshua H. Grabar at jgrabar@grabarlaw.com, or call us at 267-507-6085. #Erasca #ERAS $ERAS
Planet Fitness, Inc. (NYSE: PLNT):
Grabar Law Office is investigating claims on behalf of shareholders of Planet Fitness, Inc. (NYSE: PLNT).
What is The Investigation About? The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.
If you purchased Planet Fitness, Inc. (NYSE: PLNT), shares prior to November 6, 2025, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Visit https://grabarlaw.com/the-latest/plnt-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085 to learn more.
What is Alleged? It is alleged in a recently filed securities fraud class action complaint, that Planet Fitness, Inc. (NYSE: PLNT), through certain of its executives, violated federal securities laws by making false and/or misleading statements regarding Planet Fitness’ national rollout of an increase to its Black Card membership tier pricing and touting the ability to continue the prior year’s marketing campaign. Defendants relied upon expected membership volume growth and rate increases to present an overly rosy three-year growth algorithm. Defendants’ statements included, among other things, confidence in the Company’s brand health, its “We Are All Strong on This Planet” marketing messaging, and its purportedly resilient high-value, low-price (“HVLP”) subscription business model. Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Planet Fitness’ customer acquisition and marketing metrics. Notably, the Company’s updated marketing messaging was failing to resonate with, and was actively intimidating, its core target demographic of fitness beginners and casual gym-goers. As a result, Planet Fitness was experiencing a significant headwind in net member joins during its peak first-quarter sign-up period that rendered its previously issued fiscal 2026 guidance and long-term financial targets unachievable. Instead, Planet Fitness would be required to restructure its marketing strategy, losing the gains they praised from continuing the same marketing campaign, and entirely halt the planned Black Card price increase which sale projections were premised upon. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Planet Fitness’ securities at artificially inflated prices.
What Can You Do Now? If you purchased Planet Fitness, Inc. (NYSE: PLNT), shares prior to November 6, 2025, and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/plnt-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. #PlanetFitness #PLNT $PLNT
PROCEPT BioRobotics Corporation (NASDAQ: PRCT):
Grabar Law Office is investigating claims on behalf of shareholders of PROCEPT BioRobotics Corporation (NASDAQ: PRCT).
What is This Investigation About? The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.
If you purchased PROCEPT BioRobotics Corporation (NASDAQ: PRCT) shares before February 28, 2024, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/procept-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.
What is Alleged? As alleged in a recently filed securities fraud class action PROCEPT BioRobotics Corporation (NASDAQ: PRCT), through certain of its officers, made materially false and misleading statements and/or failed to disclose materially adverse facts including: (i) that Procept had utilized an extensive discount program designed to incentivize its customers to place bulk orders in excess of procedure demand; (ii) that Procept’s undisclosed discount program had artificially and unsustainably inflated Procept’s reported U.S. handpiece unit sales and revenues by pulling forward sales at the expense of future periods; (iii) that Procept’s undisclosed discount program had caused customer handpiece orders to materially exceed underlying procedure demand throughout the Class Period and that this differential had materially grown over time; (iv) that Procept’s consistent surplus of U.S. handpiece unit sales relative to performed procedures had created a glut of field inventory and overstocking amongst Procept’s customer base, amounting to more than 10,000 excess units by the end of the Class Period; (v) that, as a result of (i)-(iv) above, defendants’ representations regarding Procept’s handpiece unit sales and the utilization of Procept’s field Systems were materially overstated; (vi) that, as a result of (i)-(v) above, Procept was acutely exposed to material undisclosed risks of significant operational and financial harm; and (vii) that, as a result of (i)-(vi) above, Procept was unable to achieve its stated 2025 handpiece sales and revenue guidance and such guidance lacked a reasonably achievable factual basis.
What Can You Do Now? If you purchased PROCEPT BioRobotics Corporation (NASDAQ: PRCT) shares before February 28, 2024, and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/procept-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. #Procept #PRCT $PRCT
Attorney Advertising Disclaimer
Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: jgrabar@grabarlaw.com
Media gallery
